Yang Zhang1,2,3, Taiyi Jiang1, Aixin Li1, Zhen Li1,2, Jianhua Hou1,2, Meixia Gao1, Xiaojie Huang1, Bin Su1,2, Hao Wu1,2, Tong Zhang1,2, Wei Jiang3,4. 1. Center for Infectious Diseases, Beijing YouAn Hospital, Capital Medical University, Beijing, China. 2. Beijing Key Laboratory of AIDS Research, Beijing, China. 3. Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, United States. 4. Division of Infectious Diseases, Department of Medicine, Medical University of South Carolina, Charleston, SC, United States.
Abstract
Background: HIV infection results in immune homeostasis perturbations, which is characterized by CD4+ T-cell depletion, immune activation, and inflammation. Effective antiretroviral therapy (ART) does not fully restore immunologic and clinical health in people living with HIV (PLWH). Various drugs have been used to improve their immune status and CD4+ T-cell counts, but no measures have been tested effective. Here we conduct a systematic review and meta-analysis of existing clinical studies on improving CD4+ T-cell count while decreasing inflammation and immune activation. Methods: We retrieved possible relevant publications from a total of five electronic databases and selected eligible studies, which dealt with outcomes of medical therapy for CD4+ T-cell count recovery, inflammation, and immune activation with or without ART. We paid particular attention to immunologic non-responders with a favorable treatment regimen. Results: Thirty-three articles were included in the systematic review and meta-analysis. However, there were no safe and effective medications specific for improving CD4+ T-cell reconstitution. The immunological benefits or adverse events mainly depend on the safety, dosage, and duration of the candidate medication use, as well as whether it is combined with ART. Conclusion: Under the "safe, combined, adequate and long (SCAL)" principles, alternative approaches are needed to accelerate the recovery of CD4+ T-cells, and to prevent adverse long-term outcomes in PLWH with standard ART treatment.
Background: HIV infection results in immune homeostasis perturbations, which is characterized by CD4+ T-cell depletion, immune activation, and inflammation. Effective antiretroviral therapy (ART) does not fully restore immunologic and clinical health in people living with HIV (PLWH). Various drugs have been used to improve their immune status and CD4+ T-cell counts, but no measures have been tested effective. Here we conduct a systematic review and meta-analysis of existing clinical studies on improving CD4+ T-cell count while decreasing inflammation and immune activation. Methods: We retrieved possible relevant publications from a total of five electronic databases and selected eligible studies, which dealt with outcomes of medical therapy for CD4+ T-cell count recovery, inflammation, and immune activation with or without ART. We paid particular attention to immunologic non-responders with a favorable treatment regimen. Results: Thirty-three articles were included in the systematic review and meta-analysis. However, there were no safe and effective medications specific for improving CD4+ T-cell reconstitution. The immunological benefits or adverse events mainly depend on the safety, dosage, and duration of the candidate medication use, as well as whether it is combined with ART. Conclusion: Under the "safe, combined, adequate and long (SCAL)" principles, alternative approaches are needed to accelerate the recovery of CD4+ T-cells, and to prevent adverse long-term outcomes in PLWH with standard ART treatment.
Authors: G A McComsey; C C Whalen; S D Mawhorter; R Asaad; H Valdez; A H Patki; J Klaumunzner; K V Gopalakrishna; L H Calabrese; M M Lederman Journal: AIDS Date: 2001-02-16 Impact factor: 4.177
Authors: Colette J Smith; Lene Ryom; Rainer Weber; Philippe Morlat; Christian Pradier; Peter Reiss; Justyna D Kowalska; Stephane de Wit; Matthew Law; Wafaa el Sadr; Ole Kirk; Nina Friis-Moller; Antonella d'Arminio Monforte; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren Journal: Lancet Date: 2014-07-19 Impact factor: 79.321
Authors: Michael M Lederman; Laura Smeaton; Kim Y Smith; Benigno Rodriguez; Minya Pu; Hongying Wang; Anne Sevin; Pablo Tebas; Scott F Sieg; Kathy Medvik; David M Margolis; Richard Pollard; Hildegund C J Ertl; Hernan Valdez Journal: J Infect Dis Date: 2006-11-02 Impact factor: 5.226
Authors: Nicholas T Funderburg; Ying Jiang; Sara M Debanne; Danielle Labbato; Steven Juchnowski; Brian Ferrari; Brian Clagett; Janet Robinson; Michael M Lederman; Grace A McComsey Journal: J Acquir Immune Defic Syndr Date: 2015-04-01 Impact factor: 3.731
Authors: Nicholas I Paton; Ruth L Goodall; David T Dunn; Samuel Franzen; Yolanda Collaco-Moraes; Brian G Gazzard; Ian G Williams; Martin J Fisher; Alan Winston; Julie Fox; Chloe Orkin; Elbushra A Herieka; Jonathan G Ainsworth; Frank A Post; Mark Wansbrough-Jones; Peter Kelleher Journal: JAMA Date: 2012-07-25 Impact factor: 56.272
Authors: Meagan P O'Brien; Peter W Hunt; Douglas W Kitch; Karin Klingman; James H Stein; Nicholas T Funderburg; Jeffrey S Berger; Pablo Tebas; Brian Clagett; Daniela Moisi; Netanya S Utay; Fran Aweeka; Judith A Aberg Journal: Open Forum Infect Dis Date: 2017-01-19 Impact factor: 3.835
Authors: Priscilla Y Hsue; Rebecca Scherzer; Peter W Hunt; Amanda Schnell; Ann F Bolger; S C Kalapus; Kristinalisa Maka; Jeffrey N Martin; Peter Ganz; Steven G Deeks Journal: J Am Heart Assoc Date: 2012-04-24 Impact factor: 5.501